"Repurposing" of Xanthine Oxidoreductase as a Nitrite Reductase: A New Paradigm for Therapeutic Targeting in Hypertension

Antioxidants and Redox Signaling

Volumn 23, Issue 4, 2015, Pages 340-353

  Khambata, Rayomand S ^a   Ghosh, Suborno M ^a   Ahluwalia, Amrita ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; NITRITE; NITRITE REDUCTASE; XANTHINE OXIDASE; VASODILATOR AGENT; XANTHINE DEHYDROGENASE;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR SYSTEM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME CHEMISTRY; ENZYME STRUCTURE; EVIDENCE BASED PRACTICE; HUMAN; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION; ANIMAL; CHEMISTRY; METABOLISM;

MAMMALIA;

ANIMALS; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; NITRITE REDUCTASES; VASODILATOR AGENTS; XANTHINE DEHYDROGENASE;

EID: 84937901448     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6254     Document Type: Review

References (142)

1. Aamand R, Dalsgaard T, Jensen FB, Simonsen U, Roepstorff A, and Fago A. Generation of nitric oxide from nitrite by carbonic anhydrase: a possible link between metabolic activity and vasodilation. Am J Physiol Heart Circ Physiol 297: H2068-H2074, 2009.
2. Abadeh S, Case PC, and Harrison R. Demonstration of xanthine oxidase in human heart. Biochem Soc Trans 20: 346S, 1992.
3. Abadeh S, Case PC, and Harrison R. Purification of xanthine oxidase from human heart. Biochem Soc Trans 21: 99S, 1993.
4. Adachi T, Fukushima T, Usami Y, and Hirano K. Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. Biochem J 289 (Pt 2): 523-527, 1993.
5. Agarwal V, Hans N, and Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-Analysis. J Clin Hypertens 15: 435-442, 2013.
6. Andrews P, Bray RC, Edwards P, and Shooter KV. The chemistry of xanthine oxidase. 11. Ultracentrifuge and gel-filtration studies on the milk enzyme. Biochem J 93: 627-632, 1964.
7. Beckman JS and Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol Cell Physiol 271: C1424-C1437, 1996.
8. Beier S, Classen HG, Loeffler K, Schumacher E, and Thoni H. Antihypertensive effect of oral nitrite uptake in the spontaneously hypertensive rat. Arzneimittelforschung 45: 258-261, 1995.
9. Berry CE and Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606, 2004.
10. Booth VH. The specificity of xanthine oxidase. Biochem J 32: 494-502, 1938.
11. Cannon PJ, Stason WB, Demartini FE, Sommers SC, and Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med 275: 457-464, 1966.
12. Carlstrom M, Persson AE, Larsson E, Hezel M, Scheffer PG, Teerlink T, Weitzberg E, and Lundberg JO. Dietary nitrate attenuates oxidative stress, prevents cardiac and renal injuries, and reduces blood pressure in salt-induced hypertension. Cardiovasc Res 89: 574-585, 2011.
13. ClassenHG, Stein-Hammer C, and Thoni H. Hypothesis: the effect of oral nitrite on blood pressure in the spontaneously hypertensive rat. Does dietary nitrate mitigate hypertension after conversion to nitrite? J Am Coll Nutr 9: 500-502, 1990.
14. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO, III, and Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med 9: 1498-1505, 2003.
15. Dejam A, Hunter CJ, Tremonti C, Pluta RM, Hon YY, Grimes G, Partovi K, Pelletier MM, Oldfield EH, Cannon RO, III, Schechter AN, and Gladwin MT. Nitrite infusion in humans and nonhuman primates. Endocrine effects, pharmacokinetics, and tolerance formation. Circulation 116: 1821-1831, 2007.
16. Della Corte E and Stirpe F. The regulation of rat-liver xanthine oxidase: activation by proteolytic enzymes. FEBS Lett 2: 83-84, 1968.
17. Dixon M and Thurlow S. Studies on xanthine oxidase: the dynamics of the oxidase system. Biochem J 18: 976-988, 1924.
18. Dixon M and Thurlow S. studies on xanthine oxidase: the reduction of nitrates. Biochem J 18: 989-992, 1924.
19. Doel JJ, Benjamin N, Hector MP, Rogers M, and Allaker RP. Evaluation of bacterial nitrate reduction in the human oral cavity. Eur J Oral Sci 113: 14-19, 2005.
20. Dupont GP, Huecksteadt TP, Marshall BC, Ryan US, Michael JR, and Hoidal JR. Regulation of xanthine dehydrogenase and xanthine oxidase activity and gene expression in cultured rat pulmonary endothelial cells. J Clin Invest 89: 197-202, 1992.
21. Eddy LJ, Stewart JR, Jones HP, Engerson TD, McCord JM, and Downey JM. Free radical-producing enzyme, xanthine oxidase, is undetectable in human hearts. Am J Physiol Heart Circ Physiol 253: H709-H711, 1987.
22. EFSA. Nitrate in vegetables. Scientific opinion of the panel on contaminants in the food chain. EFSA J 689: 1-79, 2008.
23. Eger BT, Okamoto K, Enroth C, Sato M, Nishino T, and Pai EF. Purification, crystallization and preliminary X-ray diffraction studies of xanthine dehydrogenase and xanthine oxidase isolated from bovine milk. Acta Crystallogr D Biol Crystallogr 56: 1656-1658, 2000.
24. Elion GB. The purine path to chemotherapy. Science 244: 41-47, 1989.
25. Enroth C, Eger BT,Okamoto K, NishinoT,Nishino T, and Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: structure-based mechanism of conversion. Proc Natl Acad Sci U S A 97: 10723-10728, 2000.
26. FAO/Who. Nitrate (and potential endogenous formation of N-nitroso compounds). In: WHO Food Additive series Geneva: World Health Organisation, 2003.
27. Feig DI, Soletsky B, and Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300: 924-932, 2008.
28. Forte P, Copland M, Smith LM, Milne E, Sutherland J, and Benjamin N. Basal nitric oxide synthesis in essential hypertension. Lancet 349: 837-842, 1997.
29. Friedl HP, Smith DJ, Till GO, Thomson PD, Louis DS, and Ward PA. Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol 136: 491-495, 1990.
30. Fukuto JM, Cho JY, and Switzer CH. The chemical proerties of nitric oxide and related nitrogen oxides. In: Nitric Oxide: Biology and Pathobiology, edited by Ignarro LJ. San Diego, CA: Academic Press, 2000, pp. 23-40.
31. Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M, Zimmermann F, Ruf P, Hilgenfeldt U, and Ganten U. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci U S A 89: 7806-7810, 1992.
32. George J, Carr E, Davies J, Belch JJF, and Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 114: 2508-2516, 2006.
33. Ghosh SM, Kapil V, Fuentes-Calvo I, Bubb KJ, Pearl V, Milsom AB, Khambata R, Maleki-Toyserkani S, Yousuf M, Benjamin N, Webb AJ, Caulfield MJ, Hobbs AJ, and Ahluwalia A. Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension 61: 1091-1102, 2013.
34. Godber BL, Doel JJ, Sapkota GP, Blake DR, Stevens CR, Eisenthal R, and Harrison R. Reduction of nitrite to nitric oxide catalyzed by xanthine oxidoreductase. J Biol Chem 275: 7757-7763, 2000.
35. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, and Luno J. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388-1393, 2010.
36. Granger DN, McCord JM, Parks DA, and Hollwarth ME. Xanthine oxidase inhibitors attenuate ischemia-induced vascular permeability changes in the cat intestine. Gastroenterology 90: 80-84, 1986.
37. Grau M, Hendgen-Cotta UB, Brouzos P, Drexhage C, Rassaf T, Lauer T, Dejam A, Kelm M, and Kleinbongard P. Recent methodological advances in the analysis of nitrite in the human circulation: nitrite as a biochemical parameter of the L-Arginine/NO pathway. J Chromatogr B Analyt Technol Biomed Life Sci 851: 106-123, 2007.
38. Grum CM, Gallagher KP, Kirsh MM, and Shlafer M. Absence of detectable xanthine oxidase in human myocardium. J Mol Cell Cardiol 21: 263-267, 1989.
39. Grum CM, Ragsdale RA, Ketai LH, and Shlafer M. Absence of xanthine oxidase or xanthine dehydrogenase in the rabbit myocardium. Biochem Biophys Res Commun 141: 1104-1108, 1986.
40. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG, and Channon KM. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 26: 333-339, 2006.
41. HaasM, ClassenHG, ThoniH, ClassenUG, and Drescher B. Persistent antihypertensive effect of oral nitrite supplied up to one year via the drinking water in spontaneously hypertensive rats. Arzneimittelforschung 49: 318-323, 1999.
42. HaradaM,Ishiwata H,NakamuraY,Tanimura A, and Ishidate M. Studies on in vivo formation of nitroso compounds. Food Hyg Saf Sci (Shokuhin Eiseigaku Zasshi) 15: 206-207, 1974.
43. Harris CM and Massey V. The reaction of reduced xanthine dehydrogenase with molecular oxygen: reaction kinetcs and measurement of superoxide radical. J Biol Chem 272: 8370-8379, 1997.
44. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 33: 774-797, 2002.
45. Harrison R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev 36: 363-375, 2004.
46. Hellsten-Westing Y. Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle. Histochemistry 100: 215-222, 1993.
47. Hille R. The molybdenum oxotransferases and related enzymes. Dalton Trans 42: 3029-3042, 2013.
48. Hille R andMassey V. Studies on the oxidative half-reaction of xanthine oxidase. J Biol Chem 256: 9090-9095, 1981.
49. Hille R and Nishino T. Flavoprotein structure and mechanism. Xanthine oxidase and xanthine dehydrogenase. FASEB J 9: 995-1003, 1995.
50. Houston M, Estevez A, Chumley P, Aslan M, Marklund S, Parks DA, and Freeman BA. Binding of xanthine oxidase to vascular endothelium: kinetic characterisation and oxidative impairment of nitrix oxide-dependent signaling. J Biol Chem 274: 4985-4994, 1999.
51. Hunt J and Massey V. Studies of the reductive halfreaction of milk xanthine dehydrogenase. J Biol Chem 269: 18904-18914, 1994.
52. Ishiwata H, Boriboon P, Nakamura Y, Harada M, Tanimura A, and Ishidate M. Studies on in vivo formation of nitroso compounds (II). Food Hyg Saf Sci (Shokuhin Eiseigaku Zasshi) 16: 19-24, 1975.
53. Ishiwata H, Tanimura A, and Ishidate M. Studies on in vivo formation of nitroso compounds (III). Food Hyg Saf Sci (Shokuhin Eiseigaku Zasshi) 16: 89-92, 1975.
54. Jarasch ED, Bruder G, and Heid HW. Significance of xanthine oxidase in capillary endothelial cells. Acta Physiol Scand Suppl 548: 39-46, 1986.
55. Jarasch ED, Grund C, Bruder G, Heid HW, Keenan TW, and Franke WW. Localization of xanthine oxidase in mammary-gland epithelium and capillary endothelium. Cell 25: 67-82, 1981.
56. Jones DA, Pellaton C, Velmurugan S, Andiapen M, Antoniou S, van Eijl S, Webb AJ, Westwood M, Parmar M, Mathur A, and Ahluwalia A. Randomized phase 2 trial of intra-coronary nitrite during acute myocardial infarction. Circ Res 16: 437-447, 2015.
57. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, Duranay M, Covic A, and Johnson RJ. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6: 1887-1894, 2011.
58. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, Uz E, Akcay A, Yigitoglu R, and Covic A. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 39: 1227-1233, 2007.
59. Kang D-H, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, and Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888-2897, 2002.
60. Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F, Rehman F, Arghandawi S, Pearl V, Benjamin N, Loukogeorgakis S, MacAllister R, Hobbs AJ, Webb AJ, and Ahluwalia A. Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO. Hypertension 56: 274-281, 2010.
61. Kayyali US, Donaldson C, Huang H, Abdelnour R, and Hassoun PM. Phosphorylation of xanthine dehydrogenase/oxidase in hypoxia. J Biol Chem 276: 14359-14365, 2001.
62. Kelley EE, Hock T, Khoo NKH, Richardson GR, Johnson KK, Powell PC, Giles GI, Agarwal A, Lancaster JR, Jr., and Tarpey MM. Moderate hypoxia induces xanthine oxidoreductase activity in arterial endothelial cells. Free Radic Biol Med 40: 952-959, 2006.
63. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, and Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int 67: 1739-1742, 2005.
64. Knowles RG and Moncada S. Nitric oxide synthases in mammals. Biochem J 298 (Pt 2): 249-258, 1994.
65. Kojda G and Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 43: 652-671, 1999.
66. Laakso J, Mervaala E, Himberg J-J, Terävaïnen T-L, Karppanen H, Vapaatalo H, and Lapatto R. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension 32: 902-906, 1998.
67. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, and Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens 22: 1333-1340, 2004.
68. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, and Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 27: 943-948, 2007.
69. Lanzillo JJ, Yu FS, Stevens J, and Hassoun PM. Determination of xanthine dehydrogenase mRNA by a reverse transcription-coupled competitive quantitative polymerase chain reaction assay: regulation in rat endothelial cells by hypoxia and hyperoxia. Arch Biochem Biophys 335: 377-380, 1996.
70. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO, and Weitzberg E. Effects of dietary nitrate on blood pressure in healthy volunteers. N Engl J Med 355: 2792-2793, 2006.
71. Li H, Samouilov A, Liu X, and Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidasecatalyzed nitrite reduction. Evaluation of its role in nitric oxide generation in anoxic tissues. J Biol Chem 276: 24482-24489, 2001.
72. Li H, Samouilov A, Liu X, and Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidasecatalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 42: 1150-1159, 2003.
73. Li H, Samouilov A, Liu X, and Zweier JL. Characterization of the effects of oxygen on xanthine oxidase-mediated nitric oxide formation. J Biol Chem 279: 16939-16946, 2004.
74. Linder N, Rapola J, and Raivio KO. Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest 79: 967-974, 1999.
75. Lundberg JO and Govoni M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med 37: 395-400, 2004.
76. Lundberg JO, Weitzberg E, and Gladwin MT. The nitratenitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7: 156-167, 2008.
77. Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, Thomas P, Ashrafian H, Born GV, James PE, and Frenneaux MP. Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation 117: 670-677, 2008.
78. Málek F, Ostádal P, Parenica J, JarkovskýJ, Vítovec J, WidimskýP, Linhart A, Fedorco M, Coufal Z, Miklík R, Kr}uger A, VondrakováD, and S ? pinar J. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure-results of the Acute HEart FAilure Database registry. J Crit Care 27: 737.e11-e24, 2012.
79. Massey V, Brumby PE, and Komai H. Studies on milk xanthine oxidase. Some spectral and kinetic properties. J Biol Chem 244: 1682-1691, 1969.
80. Massey V, Komai H, Palmer G, and Elion GB. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem 245: 2837-2844, 1970.
81. Maurice C and Nasr G. Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res 1: 191-195, 2010.
82. Mazzali M, Hughes J, Kim Y-G, Jefferson JA, Kang D-H, Gordon KL, Lan HY, Kivlighn S, and Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106, 2001.
83. Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig DI, and Johnson RJ. Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 12: 108-117, 2010.
84. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 312: 159-163, 1985.
85. Millar TM, Stevens CR, Benjamin N, Eisenthal R, Harrison R, and Blake DR. Xanthine oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under hypoxic conditions. FEBS Lett 427: 225-228, 1998.
86. Momeni A, Shahidi S, Seirafian S, Taheri S, and Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis 4: 128-132, 2010.
87. Moncada S and Higgs A. The L-Arginine-nitric oxide pathway. N Engl J Med 329: 2002-2012, 1993.
88. Montenegro MF, Amaral JH, Pinheiro LC, Sakamoto EK, Ferreira GC, Reis RI, Marcal DMO, Pereira RP, and Tanus-Santos JE. Sodium nitrite downregulates vascular NADPH oxidase and exerts antihypertensive effects in hypertension. Free Radic Biol Med 51: 144-152, 2011.
89. Morgan H, Stewart CP, and Hopkins FG. On the anaerobic and aerobic oxidation of xanthin and hypoxanthin by tissues and by milk. Proc R Soc Lond 94: 109-131, 1922.
90. Moshage H, Kok B, Huizenga JR, and Jansen PL. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 41: 892-896, 1995.
91. Nielsen VG, Weinbroum A, Tan S, Samuelson PN, Gelman S, and Parks DA. Xanthine oxidoreductase release after descending thoracic aorta occlusion and reperfusion in rabbits. J Thorac Cardiovasc Surg 107: 1222-1227, 1994.
92. Noman A, Ang DSC, Ogston S, Lang CC, and Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 375: 2161-2167, 2010.
93. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, and Nishino T. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278: 1848-1855, 2003.
94. Okamoto K, Kusano T, and Nishino T. Chemical nature and reaction mechanisms of the molybdenum cofactor of xanthine oxidoreductase. Curr PharmDes 19: 2606-2614, 2013.
95. Okamoto K and Nishino T. Mechanism of inhibition of xanthine oxidase with a new tight binding inhibitor. J Biol Chem 270: 7816-7821, 1995.
96. Omar SA, Fok H, Tilgner KD, Nair A, Hunt J, Jiang B, Taylor P, Chowienczyk P, and Webb A. Paradoxical normoxia-dependent selective actions of inorganic nitrite in human muscular conduit arteries and related selective actions on central blood pressures. Circulation 131: 381-389, 2015.
97. Ong SLH, Vickers JJ, Zhang Y, McKenzie KUS, Walsh CE, and Whitworth JA. Role of xanthine oxidase in dexamethasone-induced hypertension in rats. Clin Exp Pharmacol Physiol 34: 517-519, 2007.
98. Pacher P, Nivorozhkin A, and Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58: 87-114, 2006.
99. Pannala AS, Mani AR, Spencer JP, Skinner V, Bruckdorfer KR, Moore KP, and Rice-Evans CA. The effect of dietary nitrate on salivary, plasma, and urinary nitrate metabolism in humans. Free Radic Biol Med 34: 576-584, 2003.
100. Peixoto MR, Monego ET, Jardim PC, Carvalho MM, Sousa AL, Oliveira JS, and Balestra Neto O. Diet and medication in the treatment of hyperuricemia in hypertensive patients. Arq Bras Cardiol 76: 463-472, 2001.
101. Pelletier MM, Kleinbongard P, Ringwood L, Hito R, Hunter CJ, Schechter AN, Gladwin MT, and Dejam A. The measurement of blood and plasma nitrite by chemiluminescence: pitfalls and solutions. Free Radic Biol Med 41: 541-548, 2006.
102. Petersson J, Carlstrom M, Schreiber O, Phillipson M, Christoffersson G, Jagare A, Roos S, Jansson EA, Persson AE, Lundberg JO, and Holm L. Gastroprotective and blood pressure lowering effects of dietary nitrate are abolished by an antiseptic mouthwash. Free Radic Biol Med 46: 1068-1075, 2009.
103. Pluta RM, Oldfield EH, Bakhtian KD, Fathi AR, Smith RK, DeVroom HL, Nahavandi M, Woo S, Figg WD, and Lonser RR. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One 6: e14504, 2011.
104. Poss WB, Huecksteadt TP, Panus PC, Freeman BA, and Hoidal JR. Regulation of xanthine dehydrogenase and xanthine oxidase activity by hypoxia. Am J Physiol 270: L941-L946, 1996.
105. Qin L, Liu X, Sun Q, Fan Z, Xia D,DingG,Ong HL, Adams D, Gahl WA, Zheng C, Qi S, Jin L, Zhang C, Gu L, He J, Deng D, Ambudkar IS, and Wang S. Sialin (SLC17A5) functions as a nitrate transporter in the plasma membrane. Proc Natl Acad Sci U S A 109: 13434-13439, 2012.
106. Radi R, Rubbo H, Bush K, and Freeman BA. Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys 339: 125-135, 1997.
107. Richert DA and Westerfeld WW. The relationship of iron to xanthine oxidase. J Biol Chem 209: 179-189, 1954.
108. Rouquette M, Page S, Bryant R, Benboubetra M, Stevens CR, Blake DR, Whish WD, Harrison R, and Tosh D. Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. FEBS Lett 426: 397-401, 1998.
109. Sánchez-Lozada LG, Tapia E, Soto V, A vila-Casado C, Franco M, Zhao L, and Johnson RJ. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transpl 23: 1179-1185, 2008.
110. Sanders SA, Eisenthal R, and Harrison R. NADH oxidase activity of human xanthine oxidoreductase. Eur J Biochem 245: 541-548, 1997.
111. Schardinger RZ. Über das verhalten der kuhmilch gegen methylene blau und seine verwendung zur unterscheidung von ungekochter und gekochter milch. Untersuch Nahrungs Genusmittel 5: 1113-1121, 1902.
112. Siu YP, Leung KT, Tong MK, and Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47: 51-59, 2006.
113. Soletsky B and Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 60: 1148-1156, 2012.
114. Sparacino-Watkins CE, Tejero J, Sun B, Gauthier MC, Thomas J, RagireddyV,MerchantBA,Wang J, Azarov I, Basu P, and Gladwin MT. Nitrite reductase and nitric-oxide synthase activity of themitochondrialmolybdopterin enzymesmARC1 and mARC2. J Biol Chem289: 10345-10358, 2014.
115. Spector T and Johns DG. Stoichiometric inhibition of reduced xanthine oxidase by hydroxypyrazolo[3,4-d]pyrimidines. J Biol Chem 245: 5079-5085, 1970.
116. Spiegelhalder B, Eisenbrand G, and Preussmann R. Influence of dietary nitrate on nitrite content of human saliva: possible relevance to in vivo formation of N-nitroso compounds. Food Cosmet Toxicol 14: 545-548, 1976.
117. Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschlager N, Hornig B, Drexler H, and Harrison DG. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endotheliumdependent vasodilation. Circulation 107: 1383-1389, 2003.
118. Srihirun S, Sriwantana T, Unchern S, Kittikool D, Noulsri E, Pattanapanyasat K, Fucharoen S, Piknova B, Schechter AN, and Sibmooh N. Platelet inhibition by nitrite is dependent on erythrocytes and deoxygenation. PLoS One 7: e30380, 2012.
119. Stevens CR, Millar TM, Clinch JG, Kanczler JM, Bodamyali T, and Blake DR. Antibacterial properties of xanthine oxidase in human milk. Lancet 356: 829-830, 2000.
120. Stirpe F, della Corte E, and Lorenzoni Wttao E. The regulation of rat liver xanthine oxidase: conversion in vitro of the enzyme activity from dehydrogenase (type D) and oxidase (type O). J Biol Chem 244: 3855-3863, 1969.
121. Stockert AL, Shinde SS, Anderson RF, and Hille R. The reaction mechanism of xanthine oxidase: evidence for two-electron chemistry rather than sequential one-electron steps. J Am Chem Soc 124: 14554-14555, 2002.
122. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, and Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45: 28-33, 2005.
123. Suzuki H, DeLano FA, Parks DA, Jamshidi N, Granger DN, Ishii H, SuematsuM, Zweifach BW, and Schmid-Schönbein GW.Xanthine oxidase activity associatedwith arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A 95: 4754-4759, 1998.
124. Szasz T, Davis RP, Garver HS, Burnett RJ, Fink GD, and Watts SW. Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deox- ycorticosterone acetate (DOCA)-salt hypertensive rats. PLoS One 8: e56046, 2013.
125. Tan S, Yokoyama Y, Dickens E, Cash TG, Freeman BA, and Parks DA. Xanthine oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic Biol Med 15: 407-414, 1993.
126. Tannenbaum SR, Weisman M, and Fett D. The effect of nitrate intake on nitrite formation in human saliva. Food Cosmet Toxicol 14: 549-552, 1976.
127. Tayar JH, Lopez-Olivo MA, and Suarez-Almazor ME. Febuxostat for treating chronic gout. Cochrane Database Syst Rev 11: CD008653, 2012.
128. Terada LS, Dormish JJ, Shanley PF, Leff JA, Anderson BO, and Repine JE. Circulating xanthine oxidase mediates lung neutrophil sequestration after intestinal ischemia-reperfusion. Am J Physiol 263: L394-L401, 1992.
129. Tsikas D. Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-Arginine/nitric oxide area of research. J Chromatogr B Analyt Technol Biomed Life Sci 851: 51-70, 2007.
130. van Velzen AG, Sips AJAM, Schothorst RC, Lambers AC, and Meulenbelt J. The oral bioavailability of nitrate from nitrate-rich vegetables in humans. Toxicol Lett 181: 177-181, 2008.
131. Velmurugan S, Kapil V, Ghosh SM, Davies S, McKnight A, Aboud Z, Khambata RS, Webb AJ, Poole A, and Ahluwalia A. Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med 65: 1521-1532, 2013.
132. Vleeming W, Van De Kuil A, te Biesebeek JD, Meulenbelt J, and Boink ABTJ. Effect of nitrite on blood pressure in anaesthetized and free-moving rats. Food Chem Toxicol 35: 615-619, 1997.
133. Wallwork CJ, Parks DA, and Schmid-Schönbein GW. Xanthine oxidase activity in the dexamethasone-induced hypertensive rat. Microvasc Res 66: 30-37, 2003.
134. Wang J, Krizowski S, Fischer K, Niks D, Tejero J, Wang L, Sparacino-Watkins C, Ragireddy P, Frizzell S, Kelley EE, Shiva S, Zhang Y, Basu P, Hille R, Schwarz G, and Gladwin MT. P62: sulfite oxidase catalyzes single electron transfer at molybdenum domain to reduce nitrite to NO. Nitric Oxide 31, Supplement 1: S39-S40, 2013.
135. Webb A, Bond R, McLean P, Uppal R, Benjamin N, and Ahluwalia A. Reduction of nitrite to nitric oxide during ischemia protects against myocardial ischemia-reperfusion damage. Proc Natl Acad Sci U S A 101: 13683-13688, 2004.
136. Webb AJ, Milsom AB, Rathod KS, Chu WL, Qureshi S, Lovell MJ, Lecomte FM, Perrett D, Raimondo C, Khoshbin E, Ahmed Z, Uppal R, Benjamin N, Hobbs AJ, and Ahluwalia A. Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase. Circ Res 103: 957-964, 2008.
137. Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, Rashid R, Miall P, Deanfield J, Benjamin N, MacAllister R, Hobbs AJ, and Ahluwalia A. Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite. Hypertension 51: 784-790, 2008.
138. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, Parks DA, Tarpey MM, and Freeman BA. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 93: 8745-8749, 1996.
139. Yokoyama Y, Beckman JS, Beckman TK, Wheat JK, Cash TG, Freeman BA, and Parks DA. Circulating xanthine oxidase: potential mediator of ischemic injury. Am J Physiol 258: G564-G570, 1990.
140. Zhang Z,NaughtonD,Winyard PG, BenjaminN, BlakeDR, and Symons MC. Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. BiochemBiophys ResCommun 249: 767-772, 1998.
141. Zhang Z, Naughton DP, Blake DR, Benjamin N, Stevens CR, Winyard PG, Symons MC, and Harrison R. Human xanthine oxidase converts nitrite ions into nitric oxide (NO). Biochem Soc Trans 25: 524S, 1997.
142. Zweier JL, Samouilov A, and Kuppusamy P. Non-enzymatic nitric oxide synthesis in biological systems. Biochim Biophys Acta 1411: 250-262, 1999.